Tumor-induced osteomalacia and the regulation of phosphate homeostasis

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Tumor-induced osteomalacia (TIO) is a rare and unique syndrome characterized by hypophosphatemia, excessive urinary phosphate excretion, reduced 1,25-dihydroxyvitamin D concentrations, and osteomalacia. Removal of the tumor is associated with a cure of the lesion. Several laboratories have now shown that conditioned medium derived from cultures of such tumors contain a small, heat-sensitive substance ('phosphatonin') of < 25,000 daltons that specifically inhibits sodium-dependent phosphate transport in cultured renal proximal tubular epithelia. This substance does not increase cyclic adenosine monophosphate (cAMP) formation in tubular epithelial cells and does not increase cAMP excretion in urine. A substance with similar properties is present in the circulation of patients on hemodialysis. A syndrome with a remarkably similar biochemical phenotype, namely, X-linked hypophosphatemic rickets (XLH), also has a circulating factor with properties similar, if not identical, to those of the tumor-derived factor, 'phosphatonin.' The molecular defect in XLH has been shown to be due to a mutant endopeptidase, PHEX, whose substrate might be 'phosphatonin.' Hypophosphatemia and other biochemical abnormalities in TIO are due to excessive production of 'phosphatonin' with normal PHEX function, whereas the biochemical abnormalities in XLH are caused by a mutant PHEX enzyme that fails to process 'phosphatonin.' (C) 2000 by Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalBone
Volume27
Issue number3
DOIs
StatePublished - Sep 2000

Fingerprint

Familial Hypophosphatemic Rickets
Hypophosphatemia
Homeostasis
Phosphates
Cyclic AMP
Neoplasms
Osteomalacia
Endopeptidases
Conditioned Culture Medium
Renal Dialysis
Epithelium
Hot Temperature
Epithelial Cells
Urine
Phenotype
Kidney
Enzymes
Oncogenic osteomalacia

Keywords

  • 'Phosphatonin'
  • 1,25-dihydroxyvitamin D
  • Osteomalacia
  • PHEX
  • Phosphate
  • Rickets

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Tumor-induced osteomalacia and the regulation of phosphate homeostasis. / Kumar, Rajiv.

In: Bone, Vol. 27, No. 3, 09.2000, p. 333-338.

Research output: Contribution to journalArticle

@article{4a7c43fbda5844cea38a6badc6cc8ce3,
title = "Tumor-induced osteomalacia and the regulation of phosphate homeostasis",
abstract = "Tumor-induced osteomalacia (TIO) is a rare and unique syndrome characterized by hypophosphatemia, excessive urinary phosphate excretion, reduced 1,25-dihydroxyvitamin D concentrations, and osteomalacia. Removal of the tumor is associated with a cure of the lesion. Several laboratories have now shown that conditioned medium derived from cultures of such tumors contain a small, heat-sensitive substance ('phosphatonin') of < 25,000 daltons that specifically inhibits sodium-dependent phosphate transport in cultured renal proximal tubular epithelia. This substance does not increase cyclic adenosine monophosphate (cAMP) formation in tubular epithelial cells and does not increase cAMP excretion in urine. A substance with similar properties is present in the circulation of patients on hemodialysis. A syndrome with a remarkably similar biochemical phenotype, namely, X-linked hypophosphatemic rickets (XLH), also has a circulating factor with properties similar, if not identical, to those of the tumor-derived factor, 'phosphatonin.' The molecular defect in XLH has been shown to be due to a mutant endopeptidase, PHEX, whose substrate might be 'phosphatonin.' Hypophosphatemia and other biochemical abnormalities in TIO are due to excessive production of 'phosphatonin' with normal PHEX function, whereas the biochemical abnormalities in XLH are caused by a mutant PHEX enzyme that fails to process 'phosphatonin.' (C) 2000 by Elsevier Science Inc.",
keywords = "'Phosphatonin', 1,25-dihydroxyvitamin D, Osteomalacia, PHEX, Phosphate, Rickets",
author = "Rajiv Kumar",
year = "2000",
month = "9",
doi = "10.1016/S8756-3282(00)00334-3",
language = "English (US)",
volume = "27",
pages = "333--338",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor-induced osteomalacia and the regulation of phosphate homeostasis

AU - Kumar, Rajiv

PY - 2000/9

Y1 - 2000/9

N2 - Tumor-induced osteomalacia (TIO) is a rare and unique syndrome characterized by hypophosphatemia, excessive urinary phosphate excretion, reduced 1,25-dihydroxyvitamin D concentrations, and osteomalacia. Removal of the tumor is associated with a cure of the lesion. Several laboratories have now shown that conditioned medium derived from cultures of such tumors contain a small, heat-sensitive substance ('phosphatonin') of < 25,000 daltons that specifically inhibits sodium-dependent phosphate transport in cultured renal proximal tubular epithelia. This substance does not increase cyclic adenosine monophosphate (cAMP) formation in tubular epithelial cells and does not increase cAMP excretion in urine. A substance with similar properties is present in the circulation of patients on hemodialysis. A syndrome with a remarkably similar biochemical phenotype, namely, X-linked hypophosphatemic rickets (XLH), also has a circulating factor with properties similar, if not identical, to those of the tumor-derived factor, 'phosphatonin.' The molecular defect in XLH has been shown to be due to a mutant endopeptidase, PHEX, whose substrate might be 'phosphatonin.' Hypophosphatemia and other biochemical abnormalities in TIO are due to excessive production of 'phosphatonin' with normal PHEX function, whereas the biochemical abnormalities in XLH are caused by a mutant PHEX enzyme that fails to process 'phosphatonin.' (C) 2000 by Elsevier Science Inc.

AB - Tumor-induced osteomalacia (TIO) is a rare and unique syndrome characterized by hypophosphatemia, excessive urinary phosphate excretion, reduced 1,25-dihydroxyvitamin D concentrations, and osteomalacia. Removal of the tumor is associated with a cure of the lesion. Several laboratories have now shown that conditioned medium derived from cultures of such tumors contain a small, heat-sensitive substance ('phosphatonin') of < 25,000 daltons that specifically inhibits sodium-dependent phosphate transport in cultured renal proximal tubular epithelia. This substance does not increase cyclic adenosine monophosphate (cAMP) formation in tubular epithelial cells and does not increase cAMP excretion in urine. A substance with similar properties is present in the circulation of patients on hemodialysis. A syndrome with a remarkably similar biochemical phenotype, namely, X-linked hypophosphatemic rickets (XLH), also has a circulating factor with properties similar, if not identical, to those of the tumor-derived factor, 'phosphatonin.' The molecular defect in XLH has been shown to be due to a mutant endopeptidase, PHEX, whose substrate might be 'phosphatonin.' Hypophosphatemia and other biochemical abnormalities in TIO are due to excessive production of 'phosphatonin' with normal PHEX function, whereas the biochemical abnormalities in XLH are caused by a mutant PHEX enzyme that fails to process 'phosphatonin.' (C) 2000 by Elsevier Science Inc.

KW - 'Phosphatonin'

KW - 1,25-dihydroxyvitamin D

KW - Osteomalacia

KW - PHEX

KW - Phosphate

KW - Rickets

UR - http://www.scopus.com/inward/record.url?scp=0033847087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033847087&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(00)00334-3

DO - 10.1016/S8756-3282(00)00334-3

M3 - Article

VL - 27

SP - 333

EP - 338

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -